Inside the Drug Safety Oversight Board: A Conversation with the Staff of FDA's DSB
This article was originally published in RPM Report
Executive Summary
A media briefing with the professional staff of the Drug Safety Oversight Board offered a rare opportunity for a public conversation about the activities of the group. The discussion touched on the likely role of the board in the upcoming Avandia decision, the appropriateness of closed door meetings in an era of transparency, and the evolving focus of the group five years after its formation.
You may also be interested in...
How FDA Withdraws A Drug
FDA is weighing whether to pull GlaxoSmithKline's Avandia and Abbott Laboratories' Meridia off the market. Past examples demonstrate the final decision on whether to remove a drug or keep it on the market is a messy process made by a select number of government officials.
How FDA Withdraws A Drug
FDA is weighing whether to pull GlaxoSmithKline's Avandia and Abbott Laboratories' Meridia off the market. Past examples demonstrate the final decision on whether to remove a drug or keep it on the market is a messy process made by a select number of government officials.
A July to Remember: Lessons from an Eventful Month at FDA
July 2010 may have been one of the busiest and most important months ever for the Food & Drug Administration's new drug regulatory group. Here are 10 themes to think about heading into the fall.